Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 11, 2019 06:00 ET | Source: Foamix, Ltd.

Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assetsMenlo’s serlopitant for pruritus associated with prurigo nodularis...
November 07, 2019 08:00 ET | Source: Foamix, Ltd.

Foamix Announces Issuance of New U.S. Patent for Compositions Combining a Retinoid and a Tetracycline Antibiotic

REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today...
November 04, 2019 08:00 ET | Source: Foamix, Ltd.

Foamix Announces Publication of AMZEEQ™ (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology

REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (Foamix or the Company), a specialty pharmaceutical company, announced today the...
November 01, 2019 08:00 ET | Source: Foamix, Ltd.

Foamix Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 11

REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on...
October 23, 2019 08:00 ET | Source: Foamix, Ltd.

Foamix Enters Into Manufacturing and Supply Agreement For AMZEEQ™ and FMX103

REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced...
October 21, 2019 08:00 ET | Source: Foamix, Ltd.

Foamix Announces Settlement of Litigation with Teva Relating to Finacea Foam

REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced...
October 18, 2019 16:48 ET | Source: Foamix, Ltd.

UPDATE -- Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers

AMZEEQ is the First-ever FDA Approved Topical Form of Minocycline AMZEEQ Offers Efficacy with Low Systemic Absorption REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 18, 2019 (GLOBE...
October 18, 2019 16:07 ET | Source: Foamix, Ltd.

Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers

AMZEEQ is the First-ever FDA Approved Topical Form of Minocycline AMZEEQ Offers Efficacy with Low Systemic Absorption REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 18, 2019 (GLOBE...
October 17, 2019 08:00 ET | Source: Foamix, Ltd.

Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea

REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and...
October 10, 2019 08:00 ET | Source: Foamix, Ltd.

Foamix to Present Data on its Topical Product Candidates for Acne, Rosacea at 39th Annual Fall Clinical Dermatology Conference

REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a clinical stage specialty...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right